The results show that binding of the EGF-NIR probe is specific and selective, resembling unmodified EGF, as evident from lack of competition with NRG1 and partial competition with EGF, TGF-α and Cetuximab, supporting our previous results with HT-29 CRC cell line [8]. The gene discussed is EGF; the disease is colorectal carcinoma.